News
AZTR
0.1740
-2.25%
-0.0040
Weekly Report: what happened at AZTR last week (0907-0911)?
Weekly Report · 6d ago
Azitra to Present Corporate Update at Investment Conference
TipRanks · 09/08 12:33
Weekly Report: what happened at AZTR last week (0831-0904)?
Weekly Report · 09/07 09:37
Weekly Report: what happened at AZTR last week (0824-0828)?
Weekly Report · 08/31 09:41
Weekly Report: what happened at AZTR last week (0817-0821)?
Weekly Report · 08/24 09:41
Azitra Regains NYSE American Listing Compliance Status
TipRanks · 08/21 12:29
Azitra Regains NYSE American Compliance
Benzinga · 08/21 12:02
Weekly Report: what happened at AZTR last week (0810-0814)?
Weekly Report · 08/17 09:42
Anitra Q2 EPS $(0.17) Misses $(0.12) Estimate
Benzinga · 08/12 21:02
Press Release: Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Dow Jones · 08/12 21:00
Press Release: Azitra, Inc. Announces Q2 2026 -2-
Dow Jones · 08/12 21:00
Weekly Report: what happened at AZTR last week (0803-0807)?
Weekly Report · 08/10 09:39
Weekly Report: what happened at AZTR last week (0727-0731)?
Weekly Report · 08/03 09:39
Meet Azitra: Fly Exclusive with CEO Francisco Salva
TipRanks · 07/29 18:10
Azitra building multi market microbial engineering platform, CEO says
TipRanks · 07/29 18:05
Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year
TipRanks · 07/29 18:05
CEO says breadth of Azitra’s platform opens multiple attractive markets
TipRanks · 07/29 18:05
Azitra’s ATR12-351 Trial Completion Puts Rare-Disease Skin Drug on Investors’ Radar
TipRanks · 07/29 16:30
Weekly Report: what happened at AZTR last week (0720-0724)?
Weekly Report · 07/27 09:41
Weekly Report: what happened at AZTR last week (0713-0717)?
Weekly Report · 07/20 09:39
More
Webull provides a variety of real-time AZTR stock news. You can receive the latest news about Azitra Inc through multiple platforms. This information may help you make smarter investment decisions.
About AZTR
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.